SY. NO. IDA KHAZIPALLY, KHAZIPALLY VILLAGE, JINNARAM...
Transcript of SY. NO. IDA KHAZIPALLY, KHAZIPALLY VILLAGE, JINNARAM...
ESHWAR PHARMACEUTICALS (P) LTD. (Formerly known as Konar Organics Ltd.,)
SY. NO. 180/2, IDA KHAZIPALLY, KHAZIPALLY VILLAGE, JINNARAM MANDAL,
MEDAK DISTRICT, ANDHRA PRADESH
FORM I
Project No. 0314‐21‐03March 2014
Eshwar Pharmaceuticals (P) Ltd. H.No. 7‐1‐390, Flat No. 504, Sri Sai Residency, Balkampet, SR. Nagar, Hyderabad – 500 038 Phone: +91 040‐6628 8888, 8374455510 E‐mail ID: [email protected]
STUDIES AND DOCUMENTATION BY TEAM Labs and Consultants B‐115‐117 & 509, Annapurna Block, Aditya Enclave, Ameerpet, Hyderabad‐500 038. Phone: 040‐23748 555/23748616, Telefax: 040‐23748666
SUBMITTED TO MINISTRY OF ENVIRONMENT AND FORESTS,
GOVERNMENT OF INDIA PARYAVARAN BHAVAN, LODHI ROAD, NEW DELHI
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 1
APPENDIX – I (See Paragraph – 6)
FORM I
I) Basic Information S.No. Item Details 1
Name of the Project/s M/s Eshwar Pharmaceuticals (P) Ltd., (formerly known as Konar Organics Ltd.)
2 S. No in the Schedule 5 f – A Category 3 Proposed capacity/area/length/tonnage to be
handled/command area/lease area/number of wells to be drilled
Proposed to enhance the production capacity of Active Pharma Ingredients (API’s) from 5 TPM to 20.1 TPM Cost of the project (Expansion): 2 Crores
4 New/Expansion/Modernization Expansion 5 Existing Capacity/Area etc. Existing Capacity: 5 TPM
Area Existing: 7.98 Acres 6 Category of Project i.e 'A' or 'B' “A” 7 Does it attract the general condition? If yes,
please specify No.
8 Does it attract the Specific condition? If yes, please specify.
Yes. The Unit is Located in Notified Industrial Estate / Area.
Critically Polluted Area of Pattancheru and Bollaram are located at a distance of 4 KM’s from the Site.
9 Location
Location Plan is attached in prefeasibility report
Plot/Survey/Khasra No. Sy. No. 180/2, IDA Khazipally Village Khazipally (V) Tehsil Jinnaram (M) District Medak District State Andhra Pradesh
10 Nearest railway station/airport along with distance in kms.
Nearest Railway Station is Medchal at a distance of 11 KM from the site.
11 Nearest Town, City, District Headquarters along with distance in kms.
Town & District HQ – Medak
12 Village Panchayats, Zilla Parishad, Municipal Corporation, Local body (complete postal address with telephone nos. to be given)
Khazipally Village
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 2
13 Name of the Applicant Mr.C. Chandra Shekar 14 Registered Address Eshwar Pharmaceuticals (P) Ltd.,
S.No. 180/2, IDA Khazipally, Khazipally Village, Jinnaram Mandal, Medak District – 502 319.
15 Address for Correspondence: Name Mr.C. Chandra Shekar Designation(Owner/Partner/CEO) Sr. Manager Address Eshwar Pharmaceuticals (P) Ltd.,
H.No. 7‐1‐390, Flat No. 504, Sri Sai Residency, Balkampet, SR. Nagar, Hyderabad
Pin Code 500 038 E‐mail [email protected] Telephone Number Direct : 040‐6628 8888
Mobile : +91 8374455510 Fax No. +91 40‐23551402
16 Details of alternative Sites examined, if any. Location of these sites should be shown on a topo sheet.
NA
17 Interlinked Projects ‐NA‐ 18 Whether separate application of interlinked
project has been submitted? No
19 If yes, date of submission 20 If no, reason 21 Whether the proposal involves
approval/clearance under: if yes, details of the same and their status to be given. (a) The Forest (Conservation) Act, 1980? (b) The Wildlife (Protection) Act, 1972? (c) The C.R.Z Notification, 1991?
‐NA‐
22 Whether there is any Government Order/Policy relevant/relating to the site?
No
23 Forest land involved (hectares) No 24 Whether there is any location pending against
the project and /or land in which the project is propose to be set up? (a) Name of the Court (b) Case No (c) Orders/directions of the Court, if any and its relevance with the proposed project.
No Individual Court case against the Project.
However Green Tribunal Case, W.P. No. 19661 of 2002 on the file of Hon’ble High Court of Andhra Pradesh / Application No. 90 of 2013 before NGT is filed against CETP Members.
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 3
(II) Activity 1. Construction, operation or decommissioning of the Project involving actions, which will cause physical changes in the locality (topography, land use, changes in water bodies, etc.) S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities
/rates, wherever possible) with source of information data
1.1 Permanent or temporary change in land use, land cover or topography including increase in intensity of land use (with respect to local land use plan)
NO The proposal is for expansion of API’s manufacturing capacity in the existing unit. No additional land. Total Land area after proposed expansion 7.98 Acres.
1.2 Clearance of existing land, vegetation and buildings?
NO Industrial
1.3 Creation of new land uses? NO 1.4 Pre‐construction investigations e.g.
bore houses, soil testing? YES Soil Testing completed
1.5 Construction works?
YES Construction activity involves creation of manufacturing facility and additional utilities like Chilling Plant etc.
1.6 Demolition works? NO
1.7 Temporary sites used for construction works or housing of construction workers?
NO Construction labor from local villages shall be employed.
1.8 Above ground buildings, structures orearthworks including linear structures, cut and fill or excavations
YES Storage facilities shall be constructed. No major cut and fill or excavation is anticipated.
1.9 Underground works including mining or tunneling?
NO
1.10 Reclamation works? NO 1.11 Dredging? NO 1.12 Offshore structures? NO 1.13 Production and manufacturing
processes? YES Enclosed in Annexure – I
1.14 Facilities for storage of goods or materials?
YES Raw materials and solvents shall be stored with safety precautions.
1.15 Facilities for treatment or disposal of solid waste or liquid effluents?
YES Solid waste shall be disposed to end users/recyclers or sent land fill or incineration. Effluent generated from the plant are treated and reused. Details presented in Annexure II
1.16 Facilities for long term housing of operational workers?
NO Local people shall be employed.
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 4
1.17 New road, rail or sea traffic during construction or operation?
NO
1.18 New road, rail, air waterborne or other transport infrastructure including new or altered routes and stations, ports, airports etc?
NO
1.19 Closure or diversion of existing transport routes or infrastructure leading to changes in traffic movements?
NO
1.20 New or diverted transmission lines or pipelines?
NO
1.21 Impoundment, damming, culverting, realignment or other changes to the hydrology of watercourses or aquifers?
NO
1.22 Stream crossings? NO 1.23 Abstraction or transfers of water
form ground or surface waters? YES Total water required shall increase from 41
KLD to 130.8 KLD out of which 84.8 KLD shall be met from HMWS (Industrial Supply) and the balance shall be recycled water.
1.24 Changes in water bodies or the land surface affecting drainage or run‐off?
NO
1.25 Transport of personnel or materials for construction, operation or decommissioning?
YES The construction material shall be drawn from local sources within 10 – 15 km. There is no transport of personnel, as the construction workers shall be drawn from local villages.
1.26 Long‐term dismantling or decommissioning or restoration works?
NO
1.27 Ongoing activity during decommissioning which could have an impact on the environment?
NO
1.28 Influx of people to an area in either temporarily or permanently?
YES The proposed project shall increase the employment potential and hence may lead to migration to surrounding villages.
1.29 Introduction of alien species? NO 1.30 Loss of native species or genetic
diversity? NO
1.31 Any other actions? NO
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 5
2. Use of Natural resources for construction or operation of the Project (such as land, water, materials or energy, especially any resources which are non‐renewable or in short supply): S.No. Information/checklist confirmation Yes/No Details thereof (with approximate quantities
/rates, wherever possible) with source of information data
2.1 Land especially undeveloped or agricultural land (ha)
NO Existing Unit
2.2 Water (expected source & competing users) unit: KLD
YES Total water required shall increase from 41 KLD to 130.8 KLD out of which 84.8 KLD shall be met from HMWS (Industrial Supply) and the balance shall be recycled water. (Water Balance Enclosed in Annexure III)
2.3 Minerals (MT) NA 2.4 Construction material – stone,
aggregates, sand / soil (expected source – MT)
YES Shall be sourced from the local villages.
2.5 Forests and timber (source – MT) NO 2.6 Energy including electricity and fuels
(source, competing users) Unit: fuel (MT), energy (MW)
YES The required energy shall be drawn from APTRANSCO. Backup DG sets of 2 x 125 KVA proposed and 2 x 125 KVA existing shall be provided to cater to energy requirement during load shut downs. The other energy source is existing Coal fired boiler of 0.5 TPH and 2x3TPH proposed coal fired boilers to meet the steam requirement both for process and ZLD system.
2.7 Any other natural resources (use appropriate standard units)
NO
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 6
3. Use, storage, transport, handling or production of substances or materials, which could be harmful to human health or the environment or raise concerns about actual or perceived risks to human health. S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
3.1 Use of substances or materials, which are hazardous (as per MSIHC rules) to human health or the environment (flora, fauna, and water supplies)
YES Solvents shall be used as reaction media. MSIHC rules shall be followed during storage, transportation and handling of raw materials and hazardous chemicals.
3.2 Changes in occurrence of disease or affect disease vectors (e.g. insect or water borne diseases).
NO
3.3 Affect the welfare of people e.g. by changing living conditions?
YES Shall increase the employment potential for locals and affect the living conditions for betterment.
3.4 Vulnerable groups of people who could be affected by the project e.g. hospital patients, children, the elderly etc.,
NO No sensitive receptors are present in the immediate vicinity of the site. The project shall not have any significant impact on vulnerable groups of people.
3.5 Any other causes NO
4. Production of solid wastes during construction or operation or decommissioning (MT/month) S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
4.1 Spoil, overburden or mine wastes NO 4.2 Municipal waste (domestic and or
commercial wastes) YES Wastes from canteen is generated. The
canteen wastes shall be in the range of 30 kgs/day
4.3 Hazardous wastes (as per Hazardous Waste Management Rules)
YES The quantity of hazardous waste generated during operation contain salts from evaporators, stripper distillate, process residue, and solvent residues, ETP sludge and filtration media etc. enclosed in Annexure – IV
4.4 Other industrial process wastes YES Enclosed at Annexure IV 4.5 Surplus product NO 4.6 Sewage sludge or other sludge from
effluent treatment YES Sludge from Effluent treatment plant and
Salts from MEE & ATFD shall be sent to TSDF.
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 7
4.7 Construction or demolition wastes YES Construction activity involves creation of manufacturing facility and additional utilities like Chilling Plant etc.
4.8 Redundant machinery or equipment NO
4.9 Contaminated soils or other materials NO
4.10 Agricultural wastes NO
4.11 Other solid wastes YES Enclosed at Annexure IV
5. Release of pollutants or any hazardous, toxic or noxious substances to air (Kg/hr) S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
5.1 Emissions from combustion of fossil fuels from stationary or mobile sources
YES Coal is used as fuel. Quantity of fuel and emissions details are enclosed in Annexure V
5.2 Emissions from production processes YES Enclosed in Annexure ‐ VI 5.3 Emissions from materials handling
including storage or transport NO Material transfer takes place in closed
pipeline systems. 5.4 Emissions from construction activities
including plant and equipment YES Dust may rise during transport of material and
construction activity. The dust emissions shall be mitigated by water spraying on the roads within the premises.
5.5 Dust or odors from handling of materials including construction materials, sewage and waste
YES Dust may rise during transport of material and construction activity. The dust emissions shall be mitigated by water spraying on the roads within the premises.
5.6 Emissions from incineration of waste NO 5.7 Emissions from burning of waste in
open air (e.g. slash materials, construction debris)
NO
5.8 Emissions from any other sources NO
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 8
6. Generation of Noise and Vibration, and Emissions of Light and Heat: S.No. Information/Checklist
confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data with source of information data
6.1 From operation of equipment e.g. engines, ventilation plant, crushers
YES Material transport and construction equipment shall be source of noise, while transfer pumps, vacuum systems, DG sets are the sources of noise during operation.
6.2 From industrial or similar processes
YES From DG sets, controlled by providing Acoustic Enclosures.
6.3 From construction or demolition YES Noise during construction shall be due to construction equipment and emergency DG sets.
6.4 From blasting or piling NO
6.5 From construction or operational traffic
NO The increased traffic shall not have any significant impact.
6.6 From lighting or cooling systems NO
6.7 From any other sources NO
7.Risks of contamination of land or water from releases of pollutants into the ground or into sewers, surface waters, groundwater, coastal waters or the sea: S.No. Information/Checklist
confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
7.1 From handling, storage, use or spillage of hazardous materials
NO All the hazardous materials will be stored in MS drums, in a covered shed and no contamination of soil is expected
7.2 From discharge of sewage or other effluents to water or the land (expected mode and place of discharge)
NO All the wastes from domestic operations are sent to Biological treatment in “ZLD” system.
7.3 By deposition of pollutants emitted to air into the land or into water
NO All the emissions from process are controlled by providing control equipment like scrubbers, Dust Collectors and emissions from boiler shall be controlled by providing Multi‐cone cyclone separators.
7.4 From any other sources NO 7.5 Is there a risk of long term build
up of pollutants in environment from these sources?
NO
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 9
8.Risk of accidents during construction or operation of the Project, which could affect human health or the environment S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
8.1 From explosions, spillages, fires etc from storage, handling, use or production of hazardous substances
YES All Inbuilt Safety precautions will be adopted and there will not be any damage to environment or human health
8.2 From any other causes NA 8.3 Could the project be affected by natural
disasters causing environmental damage (e.g? Floods, earthquakes, landslides, cloudburst etc)?
NO
9.Factors which should be considered (such as consequential development) which could lead to environmental effects or the potential for cumulative impacts with other existing or planned activities in the locality S. No. Information/Checklist confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
9.1 Lead to development of supporting. facilities, ancillary development or development stimulated by the project which could have impact on the environment e.g.: • Supporting infrastructure (roads, power supply, waste or waste water treatment, etc.)• housing development • extractive industries • supply industries • other
YES The project shall enhance the socio economic status of the area by increasing the demand for housing, improving the employment. There are no major support industries required for this plant.
9.2 Lead to after‐use of the site, which could haven impact on the environment
NO
9.3 Set a precedent for later developments NO 9.4 Have cumulative effects due to proximity to
other existing or planned projects with similar effects
NO The baseline environmental status of the surrounding areas is within the prescribed limits as observed from the Secondary data.
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 10
(III) Environmental Sensitivity S.No. Areas Name/
IdentityAerial distance (within 15 km.) Proposed project location boundary
1 Areas protected under international conventions, national or local legislation for their ecological, landscape, cultural or other related value
NA
2 Areas which are important or sensitive for ecological reasons ‐ Wetlands, watercourses or other water bodies, coastal zone, biospheres, mountains, forests
YES Kistaipalli RF – W ‐ 0.4 Km Kazipalli RF – SW ‐ 0.5 Km Dundigil RF – E ‐ 0.6 Km Wailalpur RF – NW ‐ 1.7 Km Pottaguda RF – NW ‐ 5.9 Km Kodakanchi RF – NW ‐ 8.5 Km Palem RF – NW ‐ 8.3 Km Jinnawaram RF – NW ‐ 6.2 Km Mangampet RF – NW ‐ 8.3 Km
3 Areas used by protected, important or sensitive species of flora or fauna for breeding, nesting, foraging, resting, over wintering, migration
NA
4 Inland, coastal, marine or underground waters NO 5 State, National boundaries NO 6 Routes or facilities used by the public for access
to recreation or other tourist, pilgrim areas NO
7 Defense installations NO 8 Densely populated or built‐up area YES Sambhupur village at 1.4 km from
site. 9 Areas occupied by sensitive man‐made land
uses (hospitals, schools, places of worship, community facilities)
NA
10 Areas containing important, high quality or scarce resources (ground water resources, surface resources, forestry, agriculture, fisheries, tourism, minerals)
NO
11 Areas already subjected to pollution or environmental damage. (those where existing legal environmental standards are exceeded)
YES Patancheru and Bollaram Industrial areas at a distance of 4Km.
12 Areas susceptible to natural hazard which could cause the project to present environmental problems (earthquakes, subsidence, landslides, erosion, flooding or extreme or adverse climatic conditions)
NO
Eshwar Pharmaceuticals (P) Ltd.
Form I Page 11
(IV) Proposed Terms of Reference for EIA studies Scope of Work of EIA “...The EIA shall cover the following: Description of the proposed project: The first task:” Description of the proposed project” forms a vital component of the Environmental Impact Assessment (EIA) as it provides the basis for evaluating the likely causes of Environmental Impacts.
Existing Environment and Baseline Conditions: The baseline assessment will be carried out to identify potentially sensitive and critical areas that may be affected by the project in an area of 10 km surrounding the project location. The critical and sensitive targets shall be plotted on land use map of project impact area. The existing environment and baseline conditions should be established from:‐ Analysis of existing information published and secondary data. ‐Consultation with relevant statutory authorities, and Field visits for supplementation of missing gaps.
The key subject areas which the EIA shall address include Ecology and Nature conservation, Air quality, surface and water quality in project impact area, soil quality, cultural heritage, landscape, land use, noise quality, etc. Natural habitats like national parks, wildlife reserves, sanctuaries, sacred grove, protected areas, forests, wetlands, major rivers and waterways if any, shall also be identified and marked.
Assessment of Environmental Impacts: Based upon the results from the review of existing information, field visits, site data collection and consultation, for each component of environment (physical, biological and socio economic) the positive, negative, direct and indirect, temporary and permanent impacts will be evaluated along with an indication of the degree of impact, i.e., whether the impact is significant, moderate, minor or negligible. The degree of impact shall also be quantified by using state of the art air quality impact prediction models based on ISCST3 algorithms.
Environment Management Plan And Mitigation Plan: For each significant negative impact identified, specialist shall work closely with the engineering team/technical consultants to suggest practicable measures to avoid or mitigate the impact. The mitigation of environmental impacts will be by three mechanisms. =>Introduction of mitigation features through the engineering practices. =>Implementation of environmental controls during construction and operation. =>Legislative control involving compliance with Indian environmental laws. The Environmental management plan shall include an estimate of capital and recurring costs of mitigation measures and will identify the institutional framework for implementation.
Monitoring Plan: Having identified the significant environmental impact that is likely to arise as a result of the project, the project team shall specify what monitoring is required during the various phases of the project cycle. The monitoring plan will identify parameters and frequency of monitoring and responsible organization.
ESHWAR PHARMACEUTICALS (P) LTD. (Formerly known as Konar Organics Ltd.,)
SY. NO. 180/2, IDA KHAZIPALLY, KHAZIPALLY VILLAGE, JINNARAM MANDAL,
MEDAK DISTRICT, ANDHRA PRADESH
ANNEXURES
SUBMITTED TO MINISTRY OF ENVIRONMENT AND FORESTS,
GOVERNMENT OF INDIA PARYAVARAN BHAVAN, LODHI ROAD, NEW DELHI
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 1
Loca
tion
Map
of E
shw
ar P
harm
aceu
tical
s (P
) Ltd
.
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 2
Plan
t Lay
out o
f Esh
war
Pha
rmac
eutic
als
(P) L
td.
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 3
ANNEXURE - I
M/s. Eshwar Pharmaceuticals (P) Ltd., obtained consent for establishment and operation for Bulk Drugs & intermediates at S. No. 180/2, IDA Khazipally, Khazipally Village, Junnaram Mandal, Medak District, Andhra Pradesh. It is proposed to expand the manufacturing capacity of API’s from 5 TPM to 20.1 TPM. The expansion entails a capital cost of Rs. 2 crores towards Manufacturing capacity enhancement, modernization of zero liquid discharge facility, debottlenecking by way of incorporating the advanced technology and state of the art equipment. Manufacturing capacity is presented in Table A-1. The proposed manufacturing capacity is presented in Table A-2.
Table A-1 Manufacturing Capacity – Permitted
S.No Product Name Capacity TPA TPM
1 Ampicillin Trihydrate 20 1.66 2 Cloxacillin Sodium 20 1.66 3 D-Glucosamine HCl 20 1.66
Total 60 5.00
Table A-2 Manufacturing Capacity – After Expansion
S.No Name of the Product Capacity TPA TPM
1 CIS-2-(2,4 Dichloro Phenyl)-2-(1H,1,2,4 Triazol-1-YL Methyl)1-3-Dioxolane-4-yl Methyl Alcohol
15 1.25
2 2,4-Di Hydo-4-{4-[4-(4-Methoxy Phenyl)-1-Piperazinyl]Phenyl}-3H 1,2,4 Triazole-3 One
20 1.67
3 N-(4-((Amino Iminomethyl Thio-Methyl)-2-Thiazolyl-Guanidine Dihydrochloride
24 2
4 N-Sulfamyl-3-Chloro Propianamide HCl 85 7.08 5 4,4-Diethoxy-N, N-Dimethyl-1-Butanamine 24 2 6 1-Methyl-4-Nitro-3N-Propylpyrazole-5-Corboxamide 24 2 7 1,3 Dichloro Acetone 24 2 8 CIS-2-Bromo Methyl-2-(2.4-Dichloro Phenyl-[1,3] Dioxolan-
4-yl Methyl Methane Sulfonate Crude 6 0.5
9 Imidazole-1yl-Acetonitrile 0.275 0.02 10 1-(2-Chloro Phenyl)-2 Methane Sulfonyloxy Ethyl Ester
Methane Sulfonic Acid 0.75 0.06
11 2-Chloromethyl-3, 4-Dimethoxy Pyridine Hydrochloride 12 1
12 S(+)-2-Aminobutyramide Hydrochloride 6 0.5 Total 241.0 20.1
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 4
Process Description of 1-(2-Chloro Phenyl)-2 Methane Sulfonyloxy Ethyl Ester Methane Sulfonic Acid - (Cis-Bromomesylate)
Reaction Scheme
Stage I
Stage II
Process Description for 1-(2-Chloro Phenyl)-2 Methane Sulfonyloxy Ethyl Ester Methane Sulfonic Acid - (Cis-Bromomesylate)
Stage I: 2,4 dichloro acetophenone reacts with glycerin in toluene to form reaction mass, to
this bromine is added in n-butanol to gets [(2S, 4R)-2-(2,4-dichlorophenyl) 2-methyl-1,3
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 5
dioxolan-4-yl] methanol. This is made to react with benzyl chloride to get Cis-bromo
benzoate.
Stage II: Cis-bromo benzoate on hydrolysis with sodium hydroxide and further
mesylation with methane sulfonyl chloride in presence of triethyl amine as alkali media to
get Methane Sulfonic acid 2- bromomethyl-2-(2,4-dichloro-phenyl)-[1,3] dioxolan-4-yl
methyl ester (Cis-bromomesylate). The process flow diagram is presented in Fig A-1 and
material balance is presented in Table A-3.
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 6
Fig A-1 Process Flow Diagram of 1-(2-Chloro Phenyl)-2 Methane Sulfonyloxy Ethyl
Ester Methane Sulfonic Acid
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 7
Table A-3 Material Balance for 1-(2-Chloro Phenyl)-2 Methane Sulfonyloxy Ethyl Ester Methane Sulfonic Acid
Stage I:
Stage II:
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 8
ANNEXURE – II: Wastewater Treatment Facilities
The effluent generated from the proposed expansion of M/s. Eshwar Pharmaceuticals (P)
Ltd., is mainly from process, washings, scrubbers, cooling towers & boiler blow downs
and domestic effluent. HTDS effluent from process, washings, scrubber and DM rejects
are sent to Stripper, Multiple Effect Evaporator followed by ATFD, Biological treatment
and RO. LTDS effluent from Cooling towers, boiler bow downs are sent to biological
treatment plant followed by RO plant. The treated effluent reused for cooling towers.
Domestic effluents sent to septic tank followed by soak pit. Total Effluent generated and
mode of treatment before and after expansion is presented in Table A-4 and quantity and
quality of effluent generated from process after expansion is presented in Table A-5.
Table A-4 Quantity of Effluent Generated – After Expansion (Tentative)
Description Quantity (KLD) Mode of Treatment Permitted After
Expansion HTDS Effluents
Process 7.45 32.87 Sent to Stripper. Stripper condensate sent to cement industries for co-processing/TSDF. Stripper bottom sent to MEE.
Washings 3
Scrubber Effluent 2 Sent to MEE followed by AFTD and biological treatment plant. DM rejects 4
Total - HTDS 7.45 41.87 LTDS Effluents
Boiler Blow downs 0.75 2 Sent to Biological Treatment System followed by RO. RO permeate reused for cooling tower makeup. RO rejects sent to MEE.
Cooling Tower Blow downs
8
Total - LTDS 0.75 10 Domestic 4.5 4.5 Sent to Septic tank followed by soak pit. Grand Total 12.7 56.37
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 9
Table A-5 Quantity and Quality of Effluent Generated from Process (Tentative)
S.No Name of the Product Quantity (Kl/day) Conc. (mg/l) Water Input
TDS COD Total Effluent
TDS COD
1 CIS-2-(2,4 Dichloro Phenyl)-2-(1H,1,2,4 Triazol-1-YL Methyl)1-3-Dioxolane-4-yl Methyl Alcohol
2.17 0.15 0.12 2.47 60566 48174
2 2,4-Di Hydo-4-{4-[4-(4-Methoxy Phenyl)-1-Piperazinyl]Phenyl}-3H 1,2,4 Triazole-3 One
2.76 0.20 0.16 3.12 62888 50020
3 N-(4-((Amino Iminomethyl Thio-Methyl)-2-Thiazolyl-Guanidine Dihydrochloride
0.27 0.03 0.02 0.32 86457 73286
4 N-Sulfamyl-3-Chloro Propianamide HCl 15.87 1.13 0.90 17.95 62888 50020 5 4,4-Diethoxy-N, N-Dimethyl-1-Butanamine 3.51 0.07 0.17 3.71 19209 44744 6 1-Methyl-4-Nitro-3N-Propylpyrazole-5-
Corboxamide 0.53 0.05 0.05 0.63 86457 73286
7 1,3 Dichloro Acetone 1.34 0.10 0.08 1.52 62888 50020 8 CIS-2-Bromo Methyl-2-(2.4-Dichloro Phenyl-
[1,3] Dioxolan-4-yl Methyl Methane Sulfonate Crude
0.64 0.01 0.02 0.68
9 Imidazole-1yl-Acetonitrile 0.05 0.00 0.01 0.06 66883 163195 10 1-(2-Chloro Phenyl)-2 Methane Sulfonyloxy
Ethyl Ester Methane Sulfonic Acid 0.09 0.00 0.01 0.11 41057 114199
11 2-Chloromethyl-3, 4-Dimethoxy Pyridine Hydrochloride
0.84 0.06 0.05 0.95 62888 50020
12 S(+)-2-Aminobutyramide Hydrochloride 1.29 0.03 0.04 1.37 21467 32851 Total 29.4 1.8 1.6 32.9 55827 49308
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 10
ANNEXURE – III: Water Balance
Water is required for process, scrubbers, washing, cooling tower makeup, steam
generation and domestic purposes. The total required water after expansion shall be
drawn from APIIC (Industrial supply) in addition to reuse of treated wastewater. The total
water requirement after expansion increased from 41 KLD to 130.8 KLD out of which 84.8
KLD fresh water and 46 KLD of recycled water. The water balance for daily consumption
after expansion is presented in Table A-6.
Table A-6 Total Water Balance – After Expansion (Tentative)
Purpose INPUT (KLD) OUTPUT (KLD) Fresh Water Recycled Water Loss Effluent
Process 30.8 32.87* Washings 3 3 Scrubber 2 2 Boiler Feed 28 26 2 Cooling Tower 10 46 48 8 RO/DM Plant 4 4 Domestic 5 0.5 4.5 Gardening 2 2 Gross Total 84.8 46 77 56.37 Total 130.8 133
* Process effluents contain soluble raw materials, byproducts, solvents etc.
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 11
ANNEXURE – IV: Solid Waste
Solid wastes are generated from the process, solvent distillation, wastewater treatment
and utilities. The effluent treatment system generates, stripper distillate, ATFD salts and
ETP sludge. The process operations generate process residue, filter media, used catalysts,
activated carbon and inorganic residue. The utilities i.e., coal fired boiler generates ash
while DG sets generate waste oil and used batteries. The hazardous wastes of process
residue, stripper distillate, solvent residue, and activated carbon are sent cement plants for
co-incineration. Mixed solvents shall be sent to authorized recyclers/cement plant for co-
incineration while spent solvents are recovered within plant premises. The inorganic
wastes, filter media, used catalysts, salts from ATFD, and ETP sludge are sent to TSDF
facility located at Dundigal, Ranga Reddy district. The waste oil and used batteries are
sold to authorized recyclers. Coal ash is sold to brick manufacturers in the local area.
The total solid waste generated and mode of disposal is presented in Table A-7.
Table A-7 Solid Waste Details – After Expansion (Tentative) Description Units After
Expansion Mode of Disposal
Ash from Boiler TPD 10.1 Sold to Brick manufactures Process Organic residue TPD 2 Sent to TSDF/Cement Industries Solvent Residue TPD 0.5 Sent to TSDF/Cement Industries Spent Carbon Kg/day 60 Sent to TSDF/Cement Industries Spent Solvents KL/Month 1000 Recovered within the plant premises. Mixed Solvents KL/Month 250 Sent to authorized recovery units/
Cement plants for co-incineration Evaporation Salts TPD 1.8 Sent to TSDF Stripper Distillate KLD 2.2 Sent to Cement Industries for Co-
incineration. ETP Sludge TPD 1.24 Sent to TSDF Detoxified containers No.s/Month 200 After detoxification sent to Authorized
agencies Waste oil Lts/Month 300 Sent to Authorized Recyclers Used batteries No.s/year 15 Sent to Authorized Recyclers
Eshwar Pharmaceuticals (P) Ltd. Form I Annexures
Page 12
ANNEXURE – V: Stack Emissions Details
The sources of air pollution in the plant are from the existing 0.5 TPH Coal fired boiler,
and proposed 2x3 TPH coal fired boilers to meet the steam requirement both for process
and ZLD and existing backup DG sets of 2x125 KVA and proposed 2 x 125 KVA, to cater
to energy requirement during load shut downs. The proposed air pollution control
equipment for coal fired boiler is Multi-Cone Cyclone separators. DG sets shall be
provided with stack heights based on the CPCB formula for effective stack height. The
emission rates of SPM, SO2, NOx and SPM from each stack are presented in Table A-8.
Table A-8 Stack Emission Details
S. No
Stack Connected to
Stack Ht (m)
Dia of stack at top(m)
Temp. of exhaust
gases (0C)
Exit Velocity (m/sec)
Pollutant Emission Rate
(g/sec)
SPM SO2 NOx
Permitted 1 0.5TPH Coal
fired Boiler 21 0.3 160 7 0.01 0.08 0.02
5 2 x 125 KVA DG Sets*
2.2 0.15 320 5 0.02 0.03 0.04
Proposed 1 2 x 3 TPH Coal
Fired Boiler 30 0.5 200 5.4 0.09 0.14 0.16
2 2 x 125 KVA DG Sets*
2.2 0.15 320 5 0.02 0.03 0.04
*DG sets will be used during load shut down by APTRANSCO.
ESHWAR PHARMACEUTICALS (P) LTD. (Formerly known as Konar Organics Ltd.,)
SY. NO. 180/2, IDA KHAZIPALLY, KHAZIPALLY VILLAGE, JINNARAM MANDAL,
MEDAK DISTRICT, ANDHRA PRADESH
STUDIES AND DOCUMENTATION BY TEAM Labs and Consultants QCI: MoE&F OM, List A-1, S.No. 150. (An ISO 9001:2008, ISO 14001:2004 & OHSAS 18001:2007 Certified Organization) B-115, Annapurna Block, Aditya Enclave Ameerpet, Hyderabad-500 038. Phone: 040-23748 555/616, Telefax: 040-23748666 Email: [email protected]